MedTrace Logo

Low Dose of Cannabidiol (CBD) to Treat Mild to Moderate Musculoskeletal Pain

NCT04193631 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-03-24

No results posted yet for this study

Summary

The purpose of the study is to evaluate whether Pure Green tablets is a better pain reliever for the treatment of mild to moderate musculoskeletal pain.

Conditions

Interventions

DRUG

Cannabidiol (CBD)

A single dose of Cannabidiol (CBD) when patients experience musculoskeletal pain in the trial.

Sponsors & Collaborators

  • Pure Green

    lead INDUSTRY

Principal Investigators

  • Debra Kimless, MD · Chief Medical Officer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-07
Primary Completion
2019-12-09
Completion
2019-12-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04193631 on ClinicalTrials.gov